|
Feb 24
|
EXEL or TECH: Which Is the Better Value Stock Right Now?
|
|
Feb 23
|
Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks
|
|
Feb 21
|
Why Exelixis Stock Trounced the Market on Thursday
|
|
Feb 21
|
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
|
|
Feb 21
|
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
|
|
Feb 20
|
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
|
|
Feb 20
|
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
|
|
Feb 20
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Feb 18
|
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
|
|
Feb 17
|
International Markets and Exelixis (EXEL): A Deep Dive for Investors
|
|
Feb 17
|
Five-year results see Exelixis’ RCC therapy extending overall survival
|
|
Feb 16
|
Exelixis Full Year 2024 Earnings: EPS Beats Expectations
|
|
Feb 15
|
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
|
|
Feb 14
|
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
|
|
Feb 13
|
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
|
|
Feb 12
|
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
|
|
Feb 12
|
Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
|
Feb 12
|
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
|
|
Feb 11
|
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Feb 11
|
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates
|